A Phase 1/2 interventional study of AURN001 and Corneal Endothelial Cells in Corneal Edema and Corneal Endothelial Dysfunction, sponsored by Aurion Biotech. Completed at 20 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-17.
Sponsored by Aurion Biotech · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Corneal Edema with a site in United States — 2 open to participants now, 3 under way, 1 of them phase 3. Corneal Edema · United States.
Among the 17 studies in Corneal Edema with a site in United States, this one is the 6th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2023, is the only one in phase 1/2, and was the 14th registered.
39 studies on the registry are indexed under Corneal Edema; 8 are open to participants now.
Browse Corneal Edema studies →2 of the 17 studies in Corneal Edema with a site in United States are open now. Recruiting first, the newest first:
Emmecell · Sites in United States
Ages 21+
University of Miami · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Corneal Edema studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 2 · Phase 4 5
First in 2005; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 52 across 31 interventional studies indexed under Corneal Edema.
Median enrollment 61 across the 14 interventional studies, 55 across the 3 observational. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 10 most frequent:
Aurion Biotech is the lead sponsor of 4 studies on the registry; none are open to participants now.
Aurion Biotech has 4 studies filed under Corneal Edema — fewer than ten, so there is no comparison to draw.
3 of the studies in Corneal Edema with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07368959Phase 3Aurion BiotechAURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction | 2027-06 |
| NCT07729137EmmecellStudy of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction | 2027-08 |
| NCT06261346University of MiamiPlasma Rich in Growth Factors in Corneal Endothelial Transplantation | 2027-10-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Corneal Edema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare different doses of AURN001 in patients with corneal edema secondary to corneal endothelial dysfunction. The main questions the clinical trial aims to answer are whether AURN001 effective and safe. Participants will receive a single injection of AURN001. A comparison between low, medium, and high doses of AURN001 against the contribution of each element, cells alone and Y27632 alone, will be conducted to determine the effects on corneal edema.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Neltependocel High and Rho-associated protein kinase
Combination Product: AURN001
Neltependocel Medium and Rho-associated protein kinase
Combination Product: AURN001
Neltependocel Low and Rho-associated protein kinase
Combination Product: AURN001
Neltependocel - High
Biological: Corneal Endothelial Cells
Rho-associated protein kinase (ROCK)
Drug: Y27632
Corneal Endothelial Cells and Y27632
Corneal Endothelial Cells
Y27632
Percentage of Participants Achieving ≥15-letter Improvement in Best-corrected Visual Acuity (BCVA) at Month 6 - Imputed Data
Best-corrected visual acuity was assessed using Early Treatment Diabetic Retinopathy Study(ETDRS) method, standard for vision testing. Standardized Sloan letter charts with 5 letters per line, decreasing by 0.1 logarithm of minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. Data presented represent number of participants with available BCVA measurements at Month 6, with those who had missing data, underwent rescue surgery before Month 6, or discontinued study prior to Month 6 imputed as non-responders.
Time frame: Month 6
Change From Baseline in BCVA at Month 6
Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.
Time frame: Baseline (Day 1) and at Month 6
Change From Baseline in Central Corneal Thickness (CCT) at Month 6
Central corneal thickness was measured by pachymetry which is an essential anatomical marker for detecting the presence or absence of edema and serves as a supportive indicator of treatment efficacy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.
Time frame: Baseline (Day 1) and at Month 6
Percentage of Participants Achieving ≥15-letter Improvement in BCVA at All Timepoints - Observed Data
Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. The data presented reflect only participants with non-missing BCVA at each corresponding visit.
Time frame: At Week 4 and at Months 2, 3, 4.5, 6, 9 and 12
Change From Baseline in BCVA at All Other Timepoints
Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.
Time frame: Baseline (Day 1) and at Week 4, Months 2, 3, 4.5, 6, 9 and 12
Change From Baseline in CCT at All Other Timepoints
Central corneal thickness was measured by pachymetry which is an essential anatomical marker for detecting the presence or absence of edema and serves as a supportive indicator of treatment efficacy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.
Time frame: Baseline (Day 1) and at Weeks 1 and 4, Months 2, 3, 4.5, 6, 9, and 12
Percentage of Participants Achieving ≥10-letter Improvement in BCVA at All Timepoints - Observed Data
Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. The data presented reflect only participants with non-missing BCVA at each corresponding visit.
Time frame: At Week 4 and at Months 2, 3, 4.5, 6, 9 and 12
This was a multicenter, randomized, double-masked, parallel-arm, dose-ranging Phase 1/2 study evaluating safety, efficacy, and tolerability of AURN001 in participants with corneal edema due to endothelial dysfunction. Three dose levels were compared with neltependocel and Y-27632 alone to assess each component's contribution on efficacy and safety of AURN001.
| Milestone | Y-27632 100 µM | Neltependocel 1.0 × 10^6 | AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) |
|---|---|---|---|---|---|
| Started | 21 | 18 | 19 | 19 | 20 |
| Completed | 3 | 12 | 7 | 12 | 17 |
| Not completed | 18 | 6 | 12 | 7 | 3 |
| Withdrew: Withdrawal by subject | 1 | 0 | 3 | 1 | 1 |
| Withdrew: Rescue | 17 | 6 | 9 | 6 | 2 |
Best-corrected visual acuity was assessed using Early Treatment Diabetic Retinopathy Study(ETDRS) method, standard for vision testing. Standardized Sloan letter charts with 5 letters per line, decreasing by 0.1 logarithm of minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. Data presented represent number of participants with available BCVA measurements at Month 6, with those who had missing data, underwent rescue surgery before Month 6, or discontinued study prior to Month 6 imputed as non-responders.
| Percentage of participants | Y-27632 100 µM | Neltependocel (1.0 × 10^6) | AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) |
|---|---|---|---|---|---|
| Percentage of Participants Achieving ≥15-letter Improvement in Best-corrected Visual Acuity (BCVA) at Month 6 - Imputed Data | 14.3 | 44.4 | 10.5 | 36.8 | 50.0 |
Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.
| change in ETDRS letters | Y-27632 100 µM | Neltependocel (1.0 × 10^6) | AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) |
|---|---|---|---|---|---|
| Change From Baseline in BCVA at Month 6 | -25.5 ± 6.06 | -5.1 ± 6.41 | -15.7 ± 6.24 | -3.0 ± 6.25 | 10.4 ± 6.17 |
Central corneal thickness was measured by pachymetry which is an essential anatomical marker for detecting the presence or absence of edema and serves as a supportive indicator of treatment efficacy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.
| Microns | Y-27632 100 µM | Neltependocel (1.0 × 10^6) | AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) |
|---|---|---|---|---|---|
| Change From Baseline in Central Corneal Thickness (CCT) at Month 6 | 67.5 ± 20.52 | -7.6 ± 22.17 | -13.8 ± 21.68 | -5.6 ± 21.91 | -14.2 ± 21.82 |
Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. The data presented reflect only participants with non-missing BCVA at each corresponding visit.
| percentage of participants | Y-27632 100 µM | Neltependocel (1.0 × 10^6) | AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) |
|---|---|---|---|---|---|
| Week 4 | 4.8 | 5.9 | 10.5 | 5.3 | 10.0 |
| Month 2 | 0 | 16.7 | 0 | 0 | 10.0 |
| Month 3 | 6.7 | 35.3 | 11.8 | 21.1 | 26.3 |
| Month 4.5 | 0 | 42.9 | 14.3 | 29.4 | 36.8 |
| Month 6 | 50.0 | 57.1 | 16.7 | 43.8 | 52.6 |
| Month 9 | 33.3 | 58.3 | 37.5 | 38.5 | 50.0 |
| Month 12 | 0 | 58.3 | 28.6 | 66.7 | 76.5 |
Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.
| change in ETDRS letters | Y-27632 100 µM | Neltependocel (1.0 × 10^6) | AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) |
|---|---|---|---|---|---|
| Week 4 | -28.7 ± 24.57 | -24.6 ± 33.16 | -27.8 ± 29.64 | -26.9 ± 25.04 | -16.9 ± 27.14 |
| Month 2 | -17.2 ± 21.69 | -20.5 ± 37.31 | -26.6 ± 29.37 | -24.3 ± 27.63 | -12.1 ± 28.37 |
| Month 3 | -19.6 ± 25.82 | -8.1 ± 40.76 | -10.6 ± 22.64 | -9.2 ± 27.96 | 0.2 ± 21.73 |
| Month 4.5 | -21.2 ± 26.51 | -8.9 ± 39.80 | -11.6 ± 26.97 | -4.1 ± 28.07 | 5.4 ± 19.90 |
| Month 6 | -21.2 ± 28.63 | -5.6 ± 40.48 | -15.2 ± 25.26 | -3.9 ± 28.30 | 6.8 ± 18.67 |
| Month 9 | -21.4 ± 28.15 | -5.5 ± 41.19 | -13.1 ± 26.36 | -3.8 ± 28.54 | 8.2 ± 18.98 |
| Month 12 | -21.5 ± 28.00 | -1.2 ± 40.29 | -14.3 ± 26.16 | -1.6 ± 30.30 | 8.8 ± 21.46 |
Central corneal thickness was measured by pachymetry which is an essential anatomical marker for detecting the presence or absence of edema and serves as a supportive indicator of treatment efficacy. Baseline was defined as the last measurement prior to the study drug injection on Day 1. Change from baseline values was calculated as follow-up visit minus baseline visit.
| Microns | Y-27632 100 µM | Neltependocel (1.0 × 10^6) | AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) |
|---|---|---|---|---|---|
| Week 1 | 87.4 ± 89.76 | 116.9 ± 134.59 | 93.4 ± 155.81 | 69.4 ± 86.47 | 117.0 ± 138.71 |
| Week 4 | 97.5 ± 117.81 | 77.3 ± 102.40 | 35.1 ± 126.58 | 40.7 ± 57.74 | 66.0 ± 78.97 |
| Month 2 | 63.7 ± 61.40 | 64.4 ± 100.38 | 47.9 ± 45.15 | 2.6 ± 45.88 | 36.9 ± 72.53 |
| Month 3 | 60.8 ± 115.35 | -4.6 ± 114.97 | -16.1 ± 94.48 | -1.6 ± 76.72 | 20.8 ± 68.96 |
| Month 4.5 | 66.9 ± 117.55 | 6.3 ± 113.65 | -25.0 ± 110.49 | -11.8 ± 76.22 | 6.8 ± 65.26 |
| Month 6 | 65.7 ± 116.75 | -5.7 ± 112.03 | -20.2 ± 110.13 | -16.7 ± 66.35 | 2.6 ± 70.27 |
| Month 9 | 64.8 ± 122.48 | -15.5 ± 112.88 | -21.0 ± 114.96 | -37.3 ± 74.17 | -21.7 ± 50.56 |
| Month 12 | 63.0 ± 114.77 | -22.4 ± 107.81 | -19.1 ± 113.35 | -31.8 ± 68.25 | -7.6 ± 89.14 |
Best-corrected visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) method, the standard for vision testing. Standardized Sloan letter charts with five letters per line, decreasing by 0.1 logarithm of the minimum angle of resolution (LogMAR) per line, were used at 4 meters (or 1 meter if ≤19 letters were read, with +0.75 spherical power added). Each correct letter equaled one point (0.02 LogMAR), with 85 letters (0.0 LogMAR) corresponding to 20/20 Snellen, 70 letters (+0.3) to 20/40, and 35 letters (+1.0) to 20/200. A gain of ≥15 letters (0.3 LogMAR, 3 lines) was clinically meaningful. Data from the study eye only were included in the analysis. Participants read letters aloud, guessing encouraged, and all responses recorded for accuracy. The data presented reflect only participants with non-missing BCVA at each corresponding visit.
| percentage of participants | Y-27632 100 µM | Neltependocel (1.0 × 10^6) | AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) |
|---|---|---|---|---|---|
| Week 4 | 4.8 | 11.8 | 15.8 | 5.3 | 10.0 |
| Month 2 | 0 | 16.7 | 14.3 | 12.5 | 40.0 |
| Month 3 | 6.7 | 47.1 | 11.8 | 31.6 | 31.6 |
| Month 4.5 | 16.7 | 50.0 | 21.4 | 35.3 | 52.6 |
| Month 6 | 50.0 | 57.1 | 16.7 | 43.8 | 57.9 |
| Month 9 | 33.3 | 83.3 | 37.5 | 53.8 | 77.8 |
| Month 12 | 33.3 | 83.3 | 42.9 | 66.7 | 82.4 |
Collected over From first dose (Day 1) through Month 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Y-27632 100 µM | 0/21 (0%) | 1/21 (4.8%) | 9/21 (42.9%) |
| Neltependocel 1.0 × 10^6 | 0/18 (0%) | 1/18 (5.6%) | 11/18 (61.1%) |
| AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) | 0/19 (0%) | 0/19 (0%) | 10/19 (52.6%) |
| AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) | 0/19 (0%) | 0/19 (0%) | 18/19 (94.7%) |
| AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) | 0/20 (0%) | 0/20 (0%) | 14/20 (70%) |
| Event | Y-27632 100 µM | Neltependocel 1.0 × 10^6 | AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) |
|---|---|---|---|---|---|
| Femur fractureInjury, poisoning and procedural complications | 0/21 | 1/18 | 0/19 | 0/19 | 0/20 |
| Hip fractureInjury, poisoning and procedural complications | 1/21 | 0/18 | 0/19 | 0/19 | 0/20 |
| Event | Y-27632 100 µM | Neltependocel 1.0 × 10^6 | AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) |
|---|---|---|---|---|---|
| Ocular hypertensionEye disorders | 3/21 | 2/18 | 3/19 | 2/19 | 1/20 |
| ConjunctivitisInfections and infestations | 0/21 | 0/18 | 0/19 | 3/19 | 0/20 |
| SinusitisInfections and infestations | 0/21 | 0/18 | 1/19 | 3/19 | 0/20 |
| Corneal abrasionInjury, poisoning and procedural complications | 0/21 | 2/18 | 0/19 | 2/19 | 0/20 |
| InfluenzaInfections and infestations | 0/21 | 2/18 | 0/19 | 0/19 | 0/20 |
| Dry eyeEye disorders | 0/21 | 0/18 | 2/19 | 0/19 | 2/20 |
| COVID-19Infections and infestations | 0/21 | 0/18 | 1/19 | 2/19 | 0/20 |
| Epiretinal membraneEye disorders | 0/21 | 0/18 | 0/19 | 2/19 | 0/20 |
| Conjunctival haemorrhageEye disorders | 2/21 | 0/18 | 1/19 | 1/19 | 2/20 |
| Endocrine ophthalmopathyEye disorders | 0/21 | 0/18 | 0/19 | 0/19 | 2/20 |
Full Analysis Set comprised of all randomized participants who received any amount of study drug during intracameral injection.
| Age, Continuous(Years) | Y-27632 100 µM | Neltependocel 1.0 × 10^6 | AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) | Total |
|---|---|---|---|---|---|---|
| Mean | 70.3 ± 9.59 | 71.3 ± 9.93 | 74.7 ± 10.32 | 69.3 ± 6.91 | 71.6 ± 8.28 | 71.4 ± 9.08 |
| Sex: Female, Male(Participants) | Y-27632 100 µM | Neltependocel 1.0 × 10^6 | AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) | Total |
|---|---|---|---|---|---|---|
| Female | 11 | 14 | 10 | 5 | 15 | 55 |
| Male | 10 | 4 | 9 | 14 | 5 | 42 |
| Ethnicity (NIH/OMB)(Participants) | Y-27632 100 µM | Neltependocel 1.0 × 10^6 | AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 0 | 0 | 2 |
| Not Hispanic or Latino | 21 | 17 | 18 | 17 | 20 | 93 |
| Unknown or Not Reported | 0 | 0 | 0 | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Y-27632 100 µM | Neltependocel 1.0 × 10^6 | AURN001 (2.5 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (5.0 × 10^5 Neltependocel + Y-27632 100 µM) | AURN001 (1.0 × 10^6 Neltependocel + Y-27632 100 µM) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 1 | 1 | 1 | 5 |
| White | 18 | 17 | 15 | 18 | 19 | 87 |
| More than one race | 0 | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 2 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2023 to primary completion in Oct 2024, 12 months.
Results were first posted in Dec 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aurion Biotech